Entrada Therapeutics (TRDA) Earnings Call Presentation

Company Overview and Pipeline - Entrada Therapeutics expects to have four active clinical programs by the end of 2025[4, 15] - The company has a strong financial position with approximately $383 million in cash, providing a cash runway into Q2 2027[5] - The company's pipeline includes programs for Duchenne Muscular Dystrophy (DMD) and Myotonic Dystrophy Type 1 (DM1), with partnered product VX-670 for DM1[14] - Entrada's Endosomal Escape Vehicle (EEV) technology aims for approximately 50% endosomal escape, compared to the standard approximately 2%[11] DMD Program Updates - ENTR-601-44: Clinical studies are authorized in the UK, EU, and US, with Phase 1/2 MAD study initiation expected in Q2 2025[4, 36, 46] - ENTR-601-45: Clinical study is authorized in the UK and EU, with Phase 1/2 MAD study initiation expected in Q3 2025[4, 38, 53] - ENTR-601-50: The company is on track to submit global regulatory filings in H2 2025, with Phase 1/2 MAD initiation expected in Q4 2025[4, 42, 65] - ENTR-601-44 Phase 1 data showed strong clinical safety up to 6 mg/kg, with potential for best-in-class pharmacokinetics and pharmacodynamics[19, 20] ENTR-601-44 Phase 1 Data Highlights - No treatment-related adverse events were reported in the ENTR-601-44-101 study up to the highest dose of 6 mg/kg[20] - At a dose of 6 mg/kg of ENTR-601-44, robust target engagement with statistically significant exon skipping was observed versus placebo[31]